NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CRIS

Curis Inc

Apr 25 • 04:00PM ET

1.63

Dollar change +0.05
Percentage change 3.16	%

Healthcare • Biotechnology • USA • NASD

Peers: BPMC TGTX KURA BIVI FATE ASND RIGL GOSS XOMA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.03	Insider Own	14.70%	Shs Outstand	10.46M	Perf Week	24.43%
Market Cap	17.05M	Forward P/E	-	EPS next Y	-2.48	Insider Trans	0.00%	Shs Float	8.92M	Perf Month	-31.80%
Income	-43.39M	PEG	-	EPS next Q	-1.17	Inst Own	40.72%	Short Float	2.31%	Perf Quarter	-52.34%
Sales	10.91M	P/S	1.56	EPS this Y	53.71%	Inst Trans	86.64%	Short Ratio	3.71	Perf Half Y	-70.09%
Book/sh	-0.71	P/B	-	EPS next Y	22.06%	ROA	-72.17%	Short Interest	0.21M	Perf Year	-89.14%
Cash/sh	1.91	P/C	0.85	EPS next 5Y	36.34%	ROE	-634.71%	52W Range	1.02 - 16.99	Perf YTD	-46.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.70%	ROI	-195.11%	52W High	-90.41%	Beta	3.70
Dividend TTM	-	Quick Ratio	1.39	Sales past 5Y	1.90%	Gross Margin	94.00%	52W Low	59.80%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	1.39	EPS Y/Y TTM	22.06%	Oper. Margin	-408.34%	RSI (14)	45.07	Volatility	10.61% 13.96%
Employees	34	Debt/Eq	-	Sales Y/Y TTM	8.83%	Profit Margin	-397.77%	Recom	1.00	Target Price	16.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	38.21%	Payout	-	Rel Volume	2.38	Prev Close	1.58
Sales Surprise	51.34%	EPS Surprise	6.72%	Sales Q/Q	24.07%	Earnings	Mar 31 BMO	Avg Volume	55.44K	Price	1.63
SMA20	14.67%	SMA50	-29.03%	SMA200	-59.53%	Trades		Volume	132,033	Change	3.16%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-23	Initiated	Truist	Buy	$26
Apr-04-22	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-13-21	Initiated	Raymond James	Outperform	$15
Mar-25-21	Initiated	B. Riley Securities	Buy	$19
Jul-29-20	Initiated	Laidlaw	Buy	$5
Jul-17-20	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-24-17	Initiated	Guggenheim	Buy	$7
Mar-02-16	Initiated	Sun Trust Rbsn Humphrey	Buy	$3
Nov-09-15	Reiterated	ROTH Capital	Buy	$6 → $5
Aug-11-15	Initiated	FBR Capital	Outperform	$6
Jan-22-15	Reiterated	Oppenheimer	Outperform	$3 → $5
Jan-21-15	Reiterated	ROTH Capital	Buy	$10 → $6
May-09-14	Reiterated	Oppenheimer	Outperform	$4.50 → $3
Oct-02-13	Initiated	Robert W. Baird	Outperform	$7
Sep-30-13	Initiated	Chardan Capital Markets	Buy	$6
Nov-14-12	Initiated	Stifel Nicolaus	Hold
Jan-31-12	Reiterated	Summer Street Research	Buy	$5 → $7
Jan-31-12	Reiterated	Brean Murray	Buy	$5 → $6
Dec-09-11	Initiated	Oppenheimer	Outperform	$6
Oct-06-11	Initiated	Summer Street Research	Buy	$5

Show Previous Ratings

Apr-12-25 11:00AM	Goldman Sachs, J&J, To Report Earnings As Investors Watch Out For Retail Sales Data (Seeking Alpha)
Apr-02-25 04:05PM	Curis to Present at Upcoming Healthcare Conference in April (PR Newswire) -10.14%
Apr-01-25 03:01AM	Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ... (GuruFocus.com) -30.48%
01:42AM	Q4 2024 Curis Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-31-25 09:59AM	Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript (Seeking Alpha) -9.48%
08:16AM	Loading…
08:16AM	Curis: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Fourth Quarter 2024 Business Update (PR Newswire)
Mar-28-25 04:07PM	Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 (PR Newswire)
Dec-10-24 08:00AM	Curis Announces Additional Data from TakeAim Leukemia Study (PR Newswire)
Nov-15-24 02:37AM	Q3 2024 Curis Inc Earnings Call (Thomson Reuters StreetEvents)
02:07AM	Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... (GuruFocus.com)
Nov-14-24 09:10AM	Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:09AM	Curis: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Third Quarter 2024 Business Update (PR Newswire)
Nov-13-24 07:31AM	Curis Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
08:00AM	Loading…
Nov-07-24 08:00AM	Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024 (PR Newswire)
Nov-02-24 11:20AM	Curis price target lowered to $20 from $26 at H.C. Wainwright (TipRanks)
Oct-29-24 06:04AM	Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement (PR Newswire) -5.89%
Oct-09-24 03:42PM	Curis Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... (GuruFocus.com)
Sep-23-24 08:30AM	Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer (PR Newswire)
Sep-17-24 07:30AM	Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference (PR Newswire) +5.11%
Sep-04-24 08:00AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire)
Aug-01-24 09:10AM	Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.85%
08:07AM	Curis: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Second Quarter 2024 Financial and Operating Update (PR Newswire)
Jul-25-24 08:00AM	Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 (PR Newswire)
Jul-10-24 07:30AM	Curis to Present at Upcoming Healthcare Conference in July (PR Newswire)
Jul-09-24 12:00PM	What Makes Curis (CRIS) a New Buy Stock (Zacks)
Jul-08-24 07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-14-24 04:00PM	Curis Announces Additional Data from TakeAim Leukemia Study (PR Newswire) -17.14%
08:00AM	Loading…
May-10-24 08:00AM	Curis to Present Updated Data from the TakeAim Leukemia Study (PR Newswire)
May-08-24 11:39AM	Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 12:53PM	CRIS Stock Earnings: Curis Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:08AM	Curis: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides First Quarter 2024 Business Update (PR Newswire)
Apr-30-24 08:00AM	Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 (PR Newswire)
Apr-05-24 08:43AM	Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength? (Zacks)
07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-04-24 07:30AM	Curis to Present at Upcoming Healthcare Conferences in April (PR Newswire) +19.48%
Feb-09-24 10:10AM	Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-08-24 08:11AM	Curis: Q4 Earnings Snapshot (Associated Press Finance) +13.42%
08:00AM	Curis Provides Fourth Quarter 2023 Business Update (PR Newswire)
Feb-01-24 08:00AM	Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 (PR Newswire)
Jan-05-24 08:00AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -9.87%
Dec-12-23 08:00AM	Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study (PR Newswire) +5.61%
Dec-11-23 08:00AM	Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference (PR Newswire) -8.89%
Dec-06-23 08:00AM	Curis Announces Three Presentations at ASH (PR Newswire) +16.50%
Dec-05-23 08:00AM	Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma (PR Newswire)
Nov-03-23 10:26AM	Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:03AM	Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year (GuruFocus.com)
Nov-02-23 08:19AM	Curis: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Third Quarter 2023 Business Update (PR Newswire)
Oct-30-23 10:00AM	2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +6.35%
Oct-26-23 08:30AM	Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 (PR Newswire)
Oct-06-23 08:56AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-22-23 03:15AM	Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock? (Zacks)
Sep-12-23 08:00AM	Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer (PR Newswire)
Sep-06-23 08:13AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire)
Aug-05-23 05:57AM	Curis, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:45PM	Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -8.82%
04:43PM	Curis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Curis Provides Second Quarter 2023 Business Update (PR Newswire)
Jul-27-23 06:25PM	Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023 (PR Newswire)
Jul-06-23 08:01AM	FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID (PR Newswire)
08:00AM	Curis Announces $15.1 Million Registered Direct Offering (PR Newswire)
Jun-30-23 06:50AM	Investors in Curis (NASDAQ:CRIS) have unfortunately lost 50% over the last five years (Simply Wall St.)
Jun-06-23 06:54AM	Is Curis, Inc. (NASDAQ:CRIS) Trading At A 47% Discount? (Simply Wall St.)
May-15-23 11:33AM	Is Curis (NASDAQ:CRIS) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-05-23 07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-04-23 05:45PM	Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Curis: Q1 Earnings Snapshot (AP Finance)
04:01PM	Curis Provides First Quarter 2023 Business Update (PR Newswire)
Apr-27-23 04:01PM	Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023 (PR Newswire) +8.76%
Apr-17-23 08:12AM	Curis, Inc. (NASDAQ:CRIS) Shares Fly 75% But Investors Aren't Buying For Growth (Simply Wall St.)
Apr-05-23 08:13PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-03-23 08:00AM	Curis to Present at Upcoming Healthcare Conferences in April (PR Newswire)
Mar-14-23 11:02AM	Curis, Inc. (NASDAQ:CRIS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-13-23 10:21PM	Q4 2022 Curis Inc Earnings Call (Thomson Reuters StreetEvents) -8.40%
09:15AM	Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Curis Provides Fourth Quarter 2022 Business Update (PR Newswire)
Mar-08-23 07:09PM	Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call (PR Newswire)
Mar-02-23 04:01PM	Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023 (PR Newswire) +8.32%
Jan-20-23 10:09AM	Investors in Curis (NASDAQ:CRIS) have unfortunately lost 80% over the last five years (Simply Wall St.)
Dec-12-22 10:00AM	Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS (PR Newswire) -15.53%
Dec-05-22 11:08PM	Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia (PR Newswire)
Nov-12-22 07:43AM	Curis Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-10-22 02:30PM	This biotech just laid off 30% of its staff. The CEO called the move 'counterintuitive' (American City Business Journals) +13.60%
Nov-09-22 05:45PM	Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.44%
04:01PM	Curis Provides Third Quarter 2022 Business Update (PR Newswire)
08:27AM	Here's Why We're Watching Curis' (NASDAQ:CRIS) Cash Burn Situation (Simply Wall St.)
Nov-07-22 04:01PM	Curis Announces Three Presentations at SITC 2022 (PR Newswire)
Nov-02-22 04:00PM	Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022 (PR Newswire)
Oct-07-22 04:01PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -6.26% -5.18%
Oct-03-22 04:01PM	Curis Announces Date for the 1st Symposium on IRAK4 in Cancer (PR Newswire) +17.20%
Sep-19-22 09:16PM	Curis Announces Date for the 2nd Annual VISTA Symposium (PR Newswire) -5.51% -6.24%
Sep-07-22 08:00AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire) +9.99%
Aug-31-22 12:53PM	Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study (Zacks)
Aug-30-22 08:52AM	Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold (Benzinga) -9.82%
08:00AM	FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study (PR Newswire)
Aug-19-22 12:25PM	Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain (Zacks) -7.14%

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRIS

Curis Inc

Upgrade your FINVIZ experience